Ruxolitinib for the treatment of severe alopecia areata

J Am Acad Dermatol. 2019 Feb;80(2):566-568. doi: 10.1016/j.jaad.2018.08.040. Epub 2018 Sep 6.

Authors

Lucy Y Liu¹, Brett A King²

Affiliations

¹ Yale University School of Medicine, New Haven, Connecticut.
² Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut. Electronic address: brett.king@yale.edu.

PMID: 30195572
DOI: 10.1016/j.jaad.2018.08.040

No abstract available

MeSH terms

Adolescent
Adult
Alopecia Areata / diagnosis*
Alopecia Areata / drug therapy*
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Hair / drug effects
Hair / growth & development*
Humans
Male
Middle Aged
Nitriles
Patient Satisfaction / statistics & numerical data
Piperidines / therapeutic use*
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Pyrroles / therapeutic use*
Retrospective Studies
Sampling Studies
Severity of Illness Index
Treatment Outcome
Young Adult

Substances

Nitriles
Piperidines
Pyrazoles
Pyrimidines
Pyrroles
ruxolitinib
tofacitinib